Antibiotic resistance transformation in community-acquired urinary infections;Evolución de la resistencia antibiótica en las infecciones urinarias adquiridas en la comunidad

Revista Clinica Espanola

Volumn 205, Issue 6, 2005, Pages 259-264

  Lorente Garin J A ^a   Placer Santos, J ^a   Salvado Costa M ^b   Segura Alvarez C ^b   Gelabert Mas, A ^a  

^a HOSPITAL DEL MAR   (Spain)

^b Laboratori de Referencia de Catalunya   (Spain)

Author keywords

Antimicrobial resistance; Community; Urinary tract infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; NITROFURANTOIN; NORFLOXACIN; PIPEMIDIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIUM TRANSFORMATION; CHILD; CONTROLLED STUDY; CYSTITIS; DRUG PREFERENCE; DRUG STABILITY; DRUG USE; EMERGENCY WARD; ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION COMPLICATION; KLEBSIELLA PNEUMONIAE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROTEUS MIRABILIS; RETROSPECTIVE STUDY; RISK FACTOR; URINARY TRACT INFECTION; URINE CULTURE;

EID: 22544450827     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13076148     Document Type: Article

References (29)

1. Vaqué J. Prevalencia de las infecciones nosocomiales en los hospitales españoles, proyecto EPIME. Barcelona: Edición de la Sociedad Española de Higiene y Medicina Preventiva Hospitalarias; 1995.
2. Stamm W, Hooton T. Management of urinary tract infections in adults. N Engl J Med. 1993;329:1328-34.
3. Huang E, Stafford R. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med. 2002;162:41-7.
4. Gupta K, Scholes D, Stamm W. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999;281:736-8.
5. Warren J, Abrutyn E, Hebel J, Johnson J, Schaeffer A, Stamm W. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999;29:745-58.
6. Aguiar J, Chacón J, Cantón R, Baquero F. The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections. J Antimicrob Chemother. 1992;29:349-50.
7. Queipo J, Budia A, Vera CC, Giménez M, Gobernado M, Jiménez-Cruz F. Susceptibility of urinary tract pathogens to quinolones. A growing problem. J Urol. 2992;167 Suppl 4:A24.
8. Gupta K, Hooton T, Stamm W. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med. 2001;135:41-50.
9. Courvalain P. Interpretative reading of antimicrobial susceptibility ests. ASM News. 1992; 58:368-75.
10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; 7th-11th informational supplement. Document M100-S7-M100-S11. National Committee for Clinical Laboratory Standards, Wayne, Pa 1997-2001.
11. Baquero F, Martínez-Beltrán J, Cantón R. Mesa Española de Normalización de la Sensibilidad y Resistencia a los Antimicrobianos (MENSURA). Criterios del grupo MENSURA para la definición de los puntos críticos de sensibilidad a los antibióticos. Rev Esp Quimioterap. 1997;10:303-13.
12. Grau S, Monterde J, Drobnic L, Salvadó M. Management of urinary tract infections: a comprehensive review. Pharm World Sci. 1997;19:236-45.
13. Ena J, Amador C, Martínez C, Ortíz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol. 1995;153:117-20.
14. Kahlmeter G. The ECO.SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother. 2000;46 Suppl 1:15-22.
15. Hooton T, Stamm W. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am. 1997;11:551-81.
16. Spencer R, Moseley D, Greensmith M. Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. J Antimicrob Chemother. 1994;33 Suppl A:121-9.
17. García-Rodríguez J, Trujillano I, Baquero F, Cisterna R, Gobernado M, Liñares F, et al. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a spanish multicenter study. J Chemother. 1997;9:394-402.
18. Dalet F, del Río F. Infecciones urinarias. Barcelona: Litofinter; 1996.
19. Schaeffer A. Infections of the urinary tract, En: Walsh P, Retik A, Vaughan E, Wein A, editors. Campbell's Urology. 7th ed. Philadelphia: Saunders; 1998. p. 533-614.
20. Gupta K, Sahm D, Mayfield D, Stamm W. Antimicrobial resistance among uropathogens that cause community-acquired tract infections in women: a nationwide analysis. Clin Infect Dis. 2001;33:89-94.
21. Goldstein F. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Eur J Clin Microbiol Infect Dis. 2000;19:112-7.
22. Goettsch W, van Pelt W, Nagelkerke N, Hendrix M, Buiting A, Petit P, et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands. J Antimicrob Chemother. 2000;46:223-8.
23. Velasco M, Horcajada J, Mensa J, Moreno-Martínez A, Vila J, Martínez J, et al. Decreased invasive capacity of quinolone-resistant Escherichia coli in patients with urinary tract infections. Clin Infect Dis. 2001;33:1682-6.
24. Alós J, Balas D, Gómez J, Grupo de Estudio de Infección en Atención Primaria. Prevalencia de susceptibilidad a quinolonas y otros antibióticos en microorganismos aislados de bacteriurias extrahospitalarias de Madrid en 1995. Rev Clin Esp. 1997;197:167-71.
25. Patel S, Balfour J, Bryson H. Fosfomycin tromethamine, a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53:637-56.
26. Zhanel G, Karlowsky J, Harding G, Carrie A, Mazzulli T, Low D, et al. A canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecilliam, nitrofurantoin, and ciprofloxacin. Antimicrob Agents Chemother. 2000;44:1089-92.
27. Schito G, Chezzi C, Nicoletti G, Moreddu M, Arcangeletti M, Stefani S, et al. Susceptibility of frequent pathogens to fosfomycin trometamol and eight other antibiotics: results of an Italian Multicenter survey. Infection. 1992;20 Suppl 4:291-5.
28. Fuchs P, Barry A, Brown S. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother. 1999;43:137-40.
29. Alós J, Gómez-Garcés J, García-Bermejo I, García-Gómez J, Gonzalez-Palacios R, Padilla B. Prevalencia de susceptibilidad de Escherichia coli a quinolonas y otros antibióticos en bacteriurias extrahospitalarias de Madrid. Med Clin (Barc). 1993;101:87-90.